[1] Yang L, Cai X, Liu J, et al. CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signaling[J]. Plos One, 2013, 8(4): e62373.
[2] Pitchai B, Ankur R, Nanjaian M. Pleiotropic actions of fenofibrate on the heart[J]. Pharmacol Res, 2011, 63(1): 8-12.
[3] Oka T, Lam VH, Zhang L, et al. Cardiac hypertrophy in the newborn delays the maturation of fatty acid β-oxidation and compromises postischemic functional recovery[J]. Am J Physiol Heart Cric Physiol, 2011, 302(9): H1784-1794.
[4] Karbowska J, Kochan Z, Smolenski RT. Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart[J]. Cell Mol Biol left, 2003, 8(1): 49-53.
[5] 颜芳, 蔡乐, 陶杰, 等. 心血管疾病经济负担的研究现状及问题[J]. 中国慢性疾病预防与控制, 2009, 17(5): 547-548.
[6] Li R, Zheng W, Pi R, et al. Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy[J]. Febs Lett, 2007, 581(17): 3311-3316.
[7] Le K, Li R, Xu S, et al. PPARαactivation inhibits endothelin-1-induced cardiomycyte hypertrohy by prewention of NFATc4 binding to GATA-4[J]. NIH Public Access, 2011, 518(1): 71-78.
[8] Zou J, Le K, Xu S, et al.Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-αpartly via preventing p65-NFκB binging to NFATc4[J]. Mol Cell Endocrinol, 2013, 370(1/2): 103-112.
[9] Purushothaman S. Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart[J]. Card Phamacol, 2011, 58(3): 254-262.
[10] Sahoko I, Koji O, Yoshiji Y, et al. Attenuation of cardiac dysfunction by a PPAR-αagonist is associated with down-regulation of redox-regulated transcription factors[J]. Mol Cell Endocrinol, 2006, 41(2): 318-329.
[11] 张峰, 曾秋棠, 李宾公, 等. 非诺贝特对糖尿病性心肌病大鼠心肌炎症和心室重构的影响[J]. 郑州大学学报, 2009, 44(1): 136-139.
[12] 叶平, 方红, 周薪, 等. 非诺贝特和吡格列酮对心肌细胞肿瘤坏死因子-α表达的影响及机制的初探[J]. 中国药学杂志, 2004, 39(4): 257-259.
[13] 李传保, 卜培莉, 张运, 等. 非诺贝特对自发性高血压大鼠心肌重构及NF-κB表达的影响[J]. 山东大学学报, 2007, 45(1): 47-50.
[14] Takehiro O, Takashi M, Satoshi S, et al. Myocardial fibrosis and diastolic dysfunction in dexycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor -kappa-b pathway[J]. Am College of Card, 2004, 43(8): 1481-1488.
[15] 吴强, 杨永, 李隆贵, 等. 非诺贝特和吡格列酮对血管紧张素Ⅱ介导的心肌细胞肥大和凋亡的干预作用[J]. 中华高血压杂志, 2007, 15(3): 233-237.
[16] Deepa S, De Silva, Wilson RM, et al. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms[J]. Am J Physiol Heart Circ Physiol, 2009, 296(6): 1983-1993.
[171] 罗文艳. PPARα/γ双激动剂的筛选及PPARγ抗糖异生作用机制的探讨[D]. 中国人民解放军军事医学科学院: 军事医学科学院放射与医学辐射研究所, 2008.
[18] Huang Y, Zhang H, Shao Z, et al. Suppression of enddothelin-1-induced cardiac myocyte hypertrophy by PPAR agonist:role of diacylglycerol kinase zeta[J]. Card Res, 2011, 90(2): 267-275.
[19] Rose M, Balakumar P, Singh M. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats[J]. Pharmacology, 2007, 80(2/3): 177-184.
[20] 万新红, 罗玉梅, 姜德谦, 等. 菲诺贝特和吡格列酮干预对代谢综合征大鼠心肌重构的影响[J]. 中国现代医学杂志, 2013, 23(4): 14-18.
[21] Wang M, Wang J, Tan R, et al. Effect of berberine on PPARα/NO activation in high glucose-and insulin-induced cardiomyocyte hypertrophy[J]. Evid Based Compl Alter Med, 2013, 2013: 285-489.
[22] 张懿玮. 病理性心肌肥大向心衰转变旳相关分子机制研究[D]. 长沙: 中南大学, 2009.
[23] 罗佳妮, 周四桂, 陈少锐, 等. 短链酯酰辅酶A脱氢酶与心肌肥大关系的初步探索[J]. 中国药理学通报, 2013, 29(5): 637-642.
[24] 刘薇, 郑强荪, 郭万刚, 等. 非诺贝特通过FOXO1抑制心肌肥大[J]. 现代生物医学进展, 2012, 12(8): 1449-1451.
[25] Rasouli N, Kern PA, Elbein SC,et al. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts[J]. Pharmaco Geno, 2012, 22(7): 484-497.
[26] Miranda S, González-Rodríguez Á, García-Ramírez M, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions[J]. J Cell Physiol, 2012, 227(6): 2352-2372.
[27] Ding F, Yu L, Wang M, et al. O-GlcNAcylation involvement in high glucose-induced cardiac hypertrophy via ERK1/2 and cyclin D2[J]. Amino Acids, 2013, 45(2): 339-349.
[28] Valene C, Xiao R, Michel P, et al. Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury[J]. Neuro Letters, 2005, 388(1): 7-12. |
